Healthcare associated infections
Victorian health services are dedicated to delivering safe, efficient and effective healthcare to the community.
A patient can develop an infection (e.g. golden staph) while receiving treatment in hospital and suffer serious consequences (e.g. prolonged hospital stay or even death). These infections can potentially be preventable.
Tap the buttons below for specific data about healthcare associated infections in public hospitals in Victoria, including golden staph infection rates. You can filter by health service.
Scroll further down for more information about the data (measures).
About the data
The above measures look at:
- rate of central line associated blood stream infections (CLABSI) in intensive care units, per 1,000 central line days
- rate of S. aureus bacteraemias (golden staph) infections per 10,000 patient days.
About central line (catheter) associated bloodstream infections (CLABSI) in ICU
CLABSI infections can occur when a patient in an Intensive Care Unit (ICU) develops an infection at the site in the body where a central line is placed.
Most infections can be prevented through proper insertion techniques and quality management and care.
Data show the number of bloodstream infections per 1,000 central line days.
About S. aureus bacteraemias (SAB) (golden staph) infections
Patients with SAB (golden staph) infections are more likely to experience complications and longer hospital stays.
Data show the number of infections per 10,000 patient/bed days (a day or part of a day a patient is admitted to hospital).
The statewide target is 1 or less SAB infections per 10,000 bed days.
- Data source: Victorian Hospital Acquired Infection Surveillance System (VICNISS). Data extracted 18 January 2021
- Results are lagged by one quarter
- Results for the current financial year are preliminary and will be finalised in November. Results from the previous financial year have been finalised
- * No results are available
- Targets for FY 2020-21 were not approved at the time of reporting for Q2 (Oct - Dec 2020) results.